Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow

Wrinkle Clinical Trial

Official title:

Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04146584
• Other study ID #: Sofwave04
• Status: Completed
• Phase: Phase 2
• Start date: November 20, 2019
• Est. completion date: March 30, 2021

Study information

• Verified date: July 2021
• Source: Sofwave Medical LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective, open label, multi-center, self-controlled clinical study to demonstrate the safety and efficacy of SofWave treatment to lift lax tissue in the submental and neck zones and to lift the eyebrow.

Description:

This is a prospective, open label, multi-center, self-controlled clinical study to demonstrate the safety and efficacy of SofWave treatment to lift lax tissue in the submental and neck zones and to lift the eyebrow.

Up to 112 healthy candidates who are seeking treatment from participating investigators will be enrolled at up to 5 participating study sites. Patients will receive 2 treatments (4-6 weeks ± 2 weeks apart) with the SofWave system and will be followed up to 3 months post the last treatment (FU2).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 93
• Est. completion date: March 30, 2021
• Est. primary completion date: March 30, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 80 Years

Eligibility

Inclusion Criteria:

1. Healthy female and male subjects between the ages 35-80.

2. Non-Smoker.

3. Fitzpatrick skin type I-VI.

4. Desire to lift lax skin in the neck and submental and/or to lift the brows.

5. Able and willing to comply with all visit, treatment and evaluation schedules and requirements.

6. Able to understand and provide written Informed Consent

7. Women of child-bearing age are required to be using a reliable method of birth control at least 3 months prior to study enrollment.

Exclusion Criteria:

1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.

2. Presence of any active systemic or local infections.

3. Presence of active local skin disease that may alter wound healing.

4. Severe solar elastosis.

5. History of Epileptic seizures.

6. History of severe migraine tendency.

7. History of smoking in past 10 years.

8. History of chronic drug or alcohol abuse.

9. Excessive subcutaneous fat on the cheeks.

10. Significant scarring in the area to be treated.

11. Severe or cystic facial acne, acutance uses during past 6 months.

12. Presence of a metal stent or implant in the facial area.

13. Inability to understand the protocol or to give informed consent.

14. On-going use of psychiatric medication.

15. History of cosmetic treatments in the facial area to be treated, including facial skin-tightening procedure within the past year; injectable filler of any type within the past year; Botox or fillers in the lower face within the past 6 months; ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep facial peels within the past 12 months; facelift, blepharoplasty, or brow lift (including contour threads) within the past 12 months.

16. Taking Isotretinoin or other oral retinoid within the past 6 months; taking psychiatric drugs, anti-platelet or anti-coagulant within the past 2 weeks.

17. As per the investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.

-

Related Conditions & MeSH terms

• Brow Lifting
• Cutis Laxa
• Skin Laxity
• Wrinkle

Intervention

Device:
• Sofwave Treatments
The device used in this study will be the SofWave system manufactured by SofWave Medical ltd. The SofWave device is an ultrasonic system combined with an inherent cooling system that generates High Intensity non-focused Ultrasonic pulses (HIUS), causing a controlled thermal damage by elevating the temperature to 60-70°C in the dermis layer while sparing the epidermal layer using surface cooling. Each patient would receive 2 Sofwave treatments on the face and/or the neck.

Locations

Country	Name	City	State
United States	Dermatology, Laser & Vein Specialists of the Carolinas	Charlotte	North Carolina
United States	Dermatology & Laser Surgery Center	Houston	Texas
United States	Laser & Skin Surgery Center of New York®	New York	New York
United States	New York Laser & Skin Care	New York	New York
United States	Laser & Skin Surgery Center of Northern California	Sacramento	California

Sponsors (1)

Lead Sponsor	Collaborator
Sofwave Medical LTD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Quantitative Photo Analysis	Photo analysis and measurements. Success criterion: point estimate of eyebrow lift > 0.5 mm Objective measurement of submental lift Success criterion: point estimate of submental lift > 20 mm. The primary endpoint would only be achieved along with success in outcome #5.	3 months post last follow up visit
Primary	Efficacy Masked Evaluators Evaluations: assessed by independent masked evaluators	Evaluate the clinical efficacy of SofWave treatment to lift lax tissue in the submental and neck zones and to lift the eyebrow, as assessed by independent masked evaluators. The two independent masked evaluators would be delivered a presentation with images randomly ordered for 'before' and 'after'. Each investigator would have to guess the correct 'after' image. Both investigators must agree on more than 50% of the cases to match success criteria. Each treated zone (Eyebrows, Neck & Submental) would be ranked individually. The primary endpoint would only be achieved along with success in outcome #5.	3 months post last treatment follow up visit
Primary	Safety Investigator Assessments	Evaluate the clinical safety of SofWave treatment to lift lax tissue in the submental and neck zones and to lift the eyebrow, as assessed by study physician. The investigator would examine the patient's skin before and after treatments and on follow up visits and would be requested to fill in a physician assessment, ranking Edema, erythema, ulceration/erosion, hypopigmentation and hyperpigmentation on a 5 option scale ranging from 0. - Absent to 4. Prominent. Safety would be checked every visit.	3 months post last treatment follow up visit
Secondary	Efficacy Investigator Assessments	Evaluate investigator assessment of clinical improvement in the treated zones using the Physician Global Aesthetic Improvement Scale (PGAIS). In this scale the treating physician would have to select the proper answer regarding treatment efficacy out of 5 options ranging from: 1. Very Much Improved to 5. Worse. Each treated zone (Eyebrows, Neck & Submental) would be ranked individually.	On the second treatment visit date (pre treatment), 3 months post last treatment follow up visit
Secondary	Subject Efficacy Assessments	Evaluate patient assessment of clinical improvement in the treated zones and treatment satisfaction using the patient satisfaction questionnaire. The patient would be given a patient satisfaction questionnaire with three questions regarding overall improvement (scale of 5 options ranging from 0. Worse to 4. Very much improved ), overall satisfaction (scale of 5 options ranging from 0. Very Satisfied to 4. Very Unsatisfied) and a question regarding willing to participate in future studies (options of Yes, No, Not sure). Each treated zone (Eyebrows, Neck & Submental) would be ranked individually.	On the second treatment visit date (pre treatment), 3 months post last treatment follow up visit